<DOC>
	<DOCNO>NCT00005045</DOCNO>
	<brief_summary>RATIONALE : Carboxyamidotriazole may stop growth kidney cancer stop blood flow tumor . PURPOSE : Phase II trial study effectiveness carboxyamidotriazole treat patient advanced kidney cancer respond biological therapy .</brief_summary>
	<brief_title>Carboxyamidotriazole Treating Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine disease free progression 6 month patient locally recurrent metastatic renal cell cancer ( refractory immunotherapy ) treat carboxyamidotriazole . II . Evaluate progression free survival rate response rate patient regimen . III . Evaluate toxic effect regimen patient . OUTLINE : Patients receive oral carboxyamidotriazole daily . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients stable disease may discontinue therapy 6 course . Patients follow every 3 month 2 year , every 6 month 3 year , every 12 month thereafter death . PROJECTED ACCRUAL : A total 55 patient accrue study within 20 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Carboxyamido-triazole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced renal cell cancer Locally recurrent metastatic lesion amenable current resection Progressive disease define 25 % increase last measurement new lesion Bidimensionally measurable disease No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 OR Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL SGOT and/or SGPT le 2 time upper limit normal Renal : Creatinine le 2.0 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No serious medical illness active infection would preclude chemotherapy compliance No prior malignancy unless curatively treated disease free past 5 year PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy At least 1 ( 2 ) prior biologic regimen ( ) ( i.e. , interleukin2 , interferon alfa , combination ) recover Regimen define least 8 week treatment Prior sargramostim allow Chemotherapy : No prior chemotherapy Endocrine therapy : At least 4 week since prior hormonal therapy ( i.e. , megestrol tamoxifen ) recover Radiotherapy : No prior radiotherapy study lesion At least 4 week since prior radiotherapy recover No concurrent palliative radiotherapy Surgery : Prior nephrectomy allow Recovered recent surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>